Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly FCF Margin of 1457.94% for Q1 2026, down 140740.0% year-over-year from N/an in Q1 2025, and down 12771.88% quarter-over-quarter from 11.33% in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported FCF Margin for 13 consecutive years, with 1457.94% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 140740.0% year-over-year to 1457.94%; the TTM figure through Mar 2026 stood at 18.24% (up 4973.0% YoY), while the FY2025 annual figure was 28.91%, up 12852.0% from the prior year.
- FCF Margin slipped to 1457.94% in Q1 2026 per LKFT's latest filing, from 11.33% in the prior quarter.
- Across five years, FCF Margin topped out at 6.36% in Q2 2025 and bottomed at 1457.94% in Q1 2026.
- Historically, FCF Margin has averaged 275.36% across 5 years, with a median of 116.29% in 2023.
- Annual changes were most pronounced in 2025 — FCF Margin surged 107813 bps — and 2026, when it tumbled 140740 bps.
- Lakefront Biotherapeutics' FCF Margin stood at 125.61% in 2022, then grew by 7 bps to 116.29% in 2023, then tumbled by 837 bps to 1089.45% in 2024, then jumped by 99 bps to 11.33% in 2025, then sank by 12772 bps to 1457.94% in 2026.
- Business Quant data shows LKFT's FCF Margin at 1457.94% in Q1 2026, 11.33% in Q4 2025, and 4.01% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,274.91% |
| Dec 31, 2025 | -5.09% |
| Sep 30, 2025 | 4.01% |
| Jun 30, 2025 | 6.36% |
| Mar 31, 2025 | -44.70% |
| Dec 31, 2024 | -143.86% |
| Sep 30, 2024 | 2.60% |
| Jun 30, 2024 | -13.21% |
| Mar 31, 2024 | -190.11% |
| Dec 31, 2023 | -71.21% |
| Mar 31, 2023 | -154.68% |
| Dec 31, 2022 | 280.12% |
| Mar 31, 2022 | -38.72% |
| Dec 31, 2021 | 538.37% |
| Jun 30, 2021 | -50.79% |
| Mar 31, 2021 | -98.97% |
| Dec 31, 2020 | -72.57% |
| Jun 30, 2020 | -135.17% |
| Mar 31, 2020 | -63.71% |
| Dec 31, 2019 | -11.04% |